Gates Foundation ramps up funding to Exscientia in COVID projectThe Bill & Melinda Gates Foundation must have liked what it saw in an initial collaboration with Exscientia Share XGates Foundation ramps up funding to Exscientia in COVID projecthttps://pharmaphorum.com/news/gates-foundation-ramps-up-funding-to-exscientia-in-covid-project/
BMS buys into AI-designed immune drug from ExscientiaBristol Myers Squibb has exercised an option on an immune-modulating drug candidate developed by UK artificial intelligence specialist Share XBMS buys into AI-designed immune drug from Exscientiahttps://pharmaphorum.com/news/exscientia/
Gates Foundation backs COVID R&D at AI firm ExscientiaArtificial intelligence-based drug discovery company Exscientia is stepping up its search for new COVID-19 medicines, thanks to an Share XGates Foundation backs COVID R&D at AI firm Exscientiahttps://pharmaphorum.com/news/gates-foundation-backs-covid-rd-at-ai-firm-exscientia/
UK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financingThe UK’s biotechnology sector is going through a purple patch, attracting almost £1.6 billion ($2.2 billion) in financing Share XUK biotech ‘booming’ as sector rakes in £1.6bn in Q2 financinghttps://pharmaphorum.com/news/uk-biotech-booming-as-sector-rakes-in-1-6bn-in-q2-financing/
Exscientia buys Allcyte to add patient sample testing to its AI platformUK-based artificial intelligence pioneer Exscientia has made a play to stay at the forefront of the field, acquiring Share XExscientia buys Allcyte to add patient sample testing to its AI platformhttps://pharmaphorum.com/news/exscientia-buys-allcyte-to-add-patient-sample-testing-to-its-ai-platform/
BMS embraces AI drug discovery with $1.2bn Exscientia allianceExscientia has signed up another big pharma partner for its artificial intelligence (AI) based drug discovery platform, this Share XBMS embraces AI drug discovery with $1.2bn Exscientia alliancehttps://pharmaphorum.com/news/bms-embraces-ai-drug-discovery-with-1-2bn-exscientia-alliance/
Exscientia starts trials of AI-designed Alzheimer’s drugExscientia has advanced a drug candidate for Alzheimer’s disease into human testing, the third clinical-stage project for the Share XExscientia starts trials of AI-designed Alzheimer’s drughttps://pharmaphorum.com/news/exscientia-starts-clinical-trials-of-ai-designed-alzheimers-drug/
Exscientia starts trials of first AI-derived cancer immunotherapyExscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) Share XExscientia starts trials of first AI-derived cancer immunotherapyhttps://pharmaphorum.com/news/exscientia-starts-trials-of-first-ai-derived-cancer-immunotherapy/
Alzheimer’s Research UK starts AI-based drug hunt with ExscientiaMedical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments Share XAlzheimer’s Research UK starts AI-based drug hunt with Exscientiahttps://pharmaphorum.com/news/alzheimers-research-uk-starts-ai-based-drug-hunt-with-exscientia/
